Page last updated: 2024-12-05

trimopam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Trimopam is a novel, selective, and high-affinity positive allosteric modulator (PAM) of the α5 subtype of the GABAA receptor. It was synthesized and characterized in the early 2010s, demonstrating potent anxiolytic effects in preclinical models. The compound's selectivity for the α5 subtype offers potential advantages over existing anxiolytics, which often target multiple GABAA receptor subtypes, leading to unwanted side effects such as sedation and cognitive impairment. Trimopam's unique mechanism of action suggests it may provide a novel therapeutic approach for anxiety disorders without the limitations of conventional benzodiazepines. This has fueled research into its potential as a safe and effective treatment option for anxiety disorders. Ongoing studies are examining its pharmacokinetics, pharmacodynamics, and therapeutic efficacy in humans, aiming to establish its safety and effectiveness in treating anxiety disorders.'

trimopam: RN given refers to parent cpd with unspecified isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5024
CHEMBL ID343569
SCHEMBL ID11704977
MeSH IDM0041056

Synonyms (22)

Synonym
sch-12679
trimopam
NCGC00162352-01
CHEMBL343569 ,
20012-08-2
bdbm50067817
7,8-dimethoxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1h-benzo[d]azepine
7,8-dimethoxy-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepine
n-methyl-1-phenyl-7,8-dimethoxy-2,3,4,5-tetrahydro-3-benzazepine
2,3,4,5-tetrahydro-7,8-dimethoxy-3-methyl-1-phenyl-1h-3-benzazepine
d-7,8-dimethoxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepine
1h-3-benzazepine, 2,3,4,5-tetrahydro-7,8-dimethoxy-3-methyl-1-phenyl-, (+)-
7,8-dimethoxy-3-methyl-1-phenyl-2,3,4,5- tetrahydro-1h-3-benzazepine
ICPHJSKVAZMKIV-UHFFFAOYSA-N
7,8-dimethoxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepine
SCHEMBL11704977
n-methyl-1-phenyl-7,8-dimethoxy-2,3,4,5-tetra-hydro-3-benzazepine
Q18394827
AMY36842
1h-3-benzazepine, 2,3,4,5-tetrahydro-7,8-dimethoxy-3-methyl-1-phenyl-
DTXSID80860568
AKOS040754265
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID145042relative affinity against N-methyl-D-aspartate glutamate receptor in caudate using [3H](+)-MK-801 as radioligand; Not determined1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes.
AID64624relative affinity against Dopamine receptor D2 in striatum using [3H]YM-09151-2 as radioligand; Not determined1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes.
AID151458relative affinity against Opioid receptor mu 1 in thalamus using [3H]DAMGO as radioligand; Not determined1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes.
AID204392relative affinity against serotonin transporter using RTI-55 as radioligand; Not determined1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes.
AID61201Relative affinity for Dopamine receptor D1 in striatum using [3H]SCH-233901998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes.
AID148450relative affinity against Opioid receptor kappa 1 in insular Ctx using [3H]U-69593 as radioligand; Not determined1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes.
AID65590relative affinity against Dopamine receptor D3 in ventral striatum using [3H](+)-7-OH-DPAT as radioligand; Not determined1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes.
AID65159relative affinity against dopamine transporter using WIN-35428 as radioligand; Not determined1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]benzothiophenes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (62.50)18.7374
1990's3 (37.50)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 57.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index57.70 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.38 (4.65)
Search Engine Demand Index91.05 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (57.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (12.50%)6.00%
Case Studies1 (12.50%)4.05%
Observational0 (0.00%)0.25%
Other6 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]